<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38450095</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1177-8881</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Drug design, development and therapy</Title><ISOAbbreviation>Drug Des Devel Ther</ISOAbbreviation></Journal><ArticleTitle>Exploration of the in vitro Antiviral Effects and the Active Components of Changyanning Tablets Against Enterovirus 71.</ArticleTitle><Pagination><StartPage>651</StartPage><EndPage>665</EndPage><MedlinePgn>651-665</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/DDDT.S444625</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">This study aims to investigate the in vitro antiviral effects of the aqueous solution of Changyanning (CYN) tablets on Enterovirus 71 (EV71), and to analyze its active components.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The in vitro anti-EV71 effects of CYN solution and its herbal ingredients were assessed by testing the relative viral RNA (vRNA) expression level and the cell viability rates. Material basis analysis was performed using HPLC-Q-TOF-MS/MS detection. Potential targets and active components were identified by network pharmacology and molecular docking. The screened components were verified by in vitro antiviral experiments.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">CYN solution exerted anti-EV71 activities as the vRNA is markedly reduced after treatment, with a half maximal inhibitory concentration (IC<sub>50</sub>) of 996.85 μg/mL. Of its five herbal ingredients, aqueous extract of <i>Mosla chinensis</i> (AEMC) and leaves of <i>Liquidambar formosana</i> Hance (AELLF) significantly inhibited the intracellular replication of EV71, and the IC<sub>50</sub> was tested as 202.57 μg/mL and 174.77 μg/mL, respectively. Based on HPLC-Q-TOF-MS/MS results, as well as the comparison with the material basis of CYN solution, a total of 44 components were identified from AEMC and AELLF. Through network pharmacology, AKT1, ALB, and SRC were identified as core targets. Molecular docking performed between core targets and the components indicated that 21 components may have anti-EV71 effects. Of these, nine were selected for in vitro pharmacodynamic verification, and only rosmarinic acid manifested in vitro anti-EV71 activity, with an IC<sub>50</sub> of 11.90 μg/mL. Moreover, rosmarinic acid can stably bind with three core targets by forming hydrogen bonds.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">CYN solution has inhibitory effects on EV71 replication in vitro, and its active component was identified as rosmarinic acid. Our study provides a new approach for screening and confirmation of the effective components in Chinese herbal preparation.</AbstractText><CopyrightInformation>© 2024 Ge et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ge</LastName><ForeName>Qiong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Key Laboratory of Public Health Detection and Etiological Research of Zhejiang Province, Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, 310051, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Zhewen</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-7350-5083</Identifier><AffiliationInfo><Affiliation>College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Zhiming</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine Pharmaceutical Technology, Zhejiang Conba Pharmaceutical Co., Ltd, Hangzhou, Zhejiang, 310057, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Changping</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Key Laboratory of Public Health Detection and Etiological Research of Zhejiang Province, Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, 310051, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Jianbiao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine Pharmaceutical Technology, Zhejiang Conba Pharmaceutical Co., Ltd, Hangzhou, Zhejiang, 310057, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Key Laboratory of Public Health Detection and Etiological Research of Zhejiang Province, Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, 310051, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Laboratory of Public Health Detection and Etiological Research of Zhejiang Province, Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, 310051, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Des Devel Ther</MedlineTA><NlmUniqueID>101475745</NlmUniqueID><ISSNLinking>1177-8881</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>MQE6XG29YI</RegistryNumber><NameOfSubstance UI="D000097123">Rosmarinic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013607">Tablets</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000097123" MajorTopicYN="N">Rosmarinic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiviral effects</Keyword><Keyword MajorTopicYN="N">component-target-pathway-disease network</Keyword><Keyword MajorTopicYN="N">core targets</Keyword><Keyword MajorTopicYN="N">material basis analysis</Keyword><Keyword MajorTopicYN="N">protein–protein interaction network</Keyword><Keyword MajorTopicYN="N">rosmarinic acid</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>7</Day><Hour>4</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38450095</ArticleId><ArticleId IdType="pmc">PMC10916518</ArticleId><ArticleId IdType="doi">10.2147/DDDT.S444625</ArticleId><ArticleId IdType="pii">444625</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sun J, Li Y, Yang Z, Fang Q, Chen B. Effect of enterovirus 71 vaccination on the epidemiological characteristics and etiology in hospitalized children with hand-foot-and-mouth disease: a retrospective study from a tertiary children’s hospital. Medicine. 2022;101(37):e30356. doi:10.1097/MD.0000000000030356</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000030356</ArticleId><ArticleId IdType="pmc">PMC9478296</ArticleId><ArticleId IdType="pubmed">36123878</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyet LA, Thanh TT, Nhan LNT, et al. Neutralizing antibodies against enteroviruses in patients with hand, foot and mouth disease. Emerg Infect Dis. 2020;26(2):298–306. doi:10.3201/eid2602.190721</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2602.190721</ArticleId><ArticleId IdType="pmc">PMC6986819</ArticleId><ArticleId IdType="pubmed">31961293</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang ZL, Mao QY, Wang YP, et al. Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum Vaccin Immunother. 2013;9(8):1701–1705. doi:10.4161/hv.24949</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.24949</ArticleId><ArticleId IdType="pmc">PMC3906269</ArticleId><ArticleId IdType="pubmed">23744508</ArticleId></ArticleIdList></Reference><Reference><Citation>Saguil A, Kane S, Lauters R, Mercado M. Hand-foot-and-mouth disease: rapid evidence review. Am Family Phys. 2019;100(7):408–414.</Citation><ArticleIdList><ArticleId IdType="pubmed">31573162</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Huang Z, Huang M, Zeng J. Predicting severe enterovirus 71-infected hand, foot, and mouth disease: cytokines and Chemokines. Mediators Inflamm. 2020;2020:9273241. doi:10.1155/2020/9273241</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/9273241</ArticleId><ArticleId IdType="pmc">PMC7013319</ArticleId><ArticleId IdType="pubmed">32089650</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S, Principi N. Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur J Clin Microbiol Infect Dis. 2018;37(3):391–398. doi:10.1007/s10096-018-3206-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-018-3206-x</ArticleId><ArticleId IdType="pubmed">29411190</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao QY, Wang Y, Bian L, Xu M, Liang Z. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines. 2016;15(5):599–606. doi:10.1586/14760584.2016.1138862</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1138862</ArticleId><ArticleId IdType="pubmed">26732723</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Z, Huang Y, Bloom MS, et al. Assessing the vaccine effectiveness for hand, foot, and mouth disease in Guangzhou, China: a time-series analysis. Hum Vaccin Immunother. 2021;17(1):217–223. doi:10.1080/21645515.2020.1763076</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1763076</ArticleId><ArticleId IdType="pmc">PMC7872061</ArticleId><ArticleId IdType="pubmed">32530733</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Yin X, Lin A, et al. EV71 vaccination impact on the incidence of encephalitis in patients with hand, foot and mouth disease. Hum Vaccines Immunother. 2021;17(7):2097–2100. doi:10.1080/21645515.2020.1851129</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1851129</ArticleId><ArticleId IdType="pmc">PMC8189069</ArticleId><ArticleId IdType="pubmed">33522390</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10(11):778–790. doi:10.1016/S1473-3099(10)70194-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K, Zhang P, Zhang Z, et al. Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: efficacies and mechanisms. Pharmacol Ther. 2021;225:107843. doi:10.1016/j.pharmthera.2021.107843</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2021.107843</ArticleId><ArticleId IdType="pmc">PMC8011334</ArticleId><ArticleId IdType="pubmed">33811957</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J, Zhang G, Xing J, Yu Y, Han T. Network meta-analysis of heat-clearing and detoxifying oral liquid of Chinese medicines in treatment of children’s hand-foot-mouth disease: a protocol for systematic review and meta-analysis. Medicine. 2022;101(5):e28778. doi:10.1097/MD.0000000000028778</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000028778</ArticleId><ArticleId IdType="pmc">PMC8812596</ArticleId><ArticleId IdType="pubmed">35119042</ArticleId></ArticleIdList></Reference><Reference><Citation>Li XH, Li SJ, Xu Y, et al. Effect of integrated Chinese and Western medicine therapy on severe hand, foot and mouth disease: a prospective, randomized, controlled trial. Chin J Integr Med. 2017;23(12):887–892. doi:10.1007/s11655-016-2504-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11655-016-2504-3</ArticleId><ArticleId IdType="pubmed">27392481</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W, Zhang Y, Kang C, et al. The pharmacological evidence of the Chang-yan-ning formula in the treatment of colitis. Front Pharmacol. 2022;13:1029088. doi:10.3389/fphar.2022.1029088</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.1029088</ArticleId><ArticleId IdType="pmc">PMC9579319</ArticleId><ArticleId IdType="pubmed">36278202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Yang F. Analysis of the therapeutic effect of changyanning on intestinal flora in inflammatory bowel disease. Contrast Media Mol Imaging. 2022;2022:3757763. doi:10.1155/2022/3757763</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/3757763</ArticleId><ArticleId IdType="pmc">PMC9242759</ArticleId><ArticleId IdType="pubmed">35845725</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo P, Wang Z, Lv X, et al. Changyanning regulates gut microbiota and metabolism to ameliorate intestinal injury induced by ETEC K88. Front Microbiol. 2023;14:1098818. doi:10.3389/fmicb.2023.1098818</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2023.1098818</ArticleId><ArticleId IdType="pmc">PMC9909429</ArticleId><ArticleId IdType="pubmed">36778862</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang N, Gao H, He L, et al. Ginsenoside Rb1 is an immune-stimulatory agent with antiviral activity against enterovirus 71. J Ethnopharmacol. 2021;266:113401. doi:10.1016/j.jep.2020.113401</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2020.113401</ArticleId><ArticleId IdType="pubmed">32980486</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Yao C, Guo DA. Insight into chemical basis of traditional Chinese medicine based on the state-of-the-art techniques of liquid chromatography-mass spectrometry. Acta Pharm Sin B. 2021;11(6):1469–1492. doi:10.1016/j.apsb.2021.02.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2021.02.017</ArticleId><ArticleId IdType="pmc">PMC8245813</ArticleId><ArticleId IdType="pubmed">34221863</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Liu J, Ma Z, Duan F, Guo Z, Xiao H. Rapid identification of chemical constituents of Rhodiola crenulata using liquid chromatography-mass spectrometry pseudotargeted analysis. J Sep Sci. 2021;44(20):3747–3776. doi:10.1002/jssc.202100342</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jssc.202100342</ArticleId><ArticleId IdType="pubmed">34407563</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Z, Pan Y, Leng T, et al. Progress and prospects of research ideas and methods in the network pharmacology of Traditional Chinese Medicine. J Pharm Pharm Sci. 2022;25:218–226. doi:10.18433/jpps32911</Citation><ArticleIdList><ArticleId IdType="doi">10.18433/jpps32911</ArticleId><ArticleId IdType="pubmed">35760072</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu YY, Yu LH, Zhang J, Xie DJ, Zhang XX, Yu JM. Network pharmacology-based and molecular docking-based analysis of suanzaoren decoction for the treatment of parkinson’s disease with sleep disorder. Biomed Res Int. 2021;2021:1752570. doi:10.1155/2021/1752570</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/1752570</ArticleId><ArticleId IdType="pmc">PMC8519686</ArticleId><ArticleId IdType="pubmed">34660782</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Liu J, Tong X, et al. Network pharmacology prediction and molecular docking-based strategy to discover the potential pharmacological mechanism of huai hua san against ulcerative colitis. Drug Des Devel Ther. 2021;15:3255–3276. doi:10.2147/DDDT.S319786</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S319786</ArticleId><ArticleId IdType="pmc">PMC8326529</ArticleId><ArticleId IdType="pubmed">34349502</ArticleId></ArticleIdList></Reference><Reference><Citation>Crampon K, Giorkallos A, Deldossi M, Baud S, Steffenel LA. Machine-learning methods for ligand-protein molecular docking. Drug Discov Today. 2022;27(1):151–164. doi:10.1016/j.drudis.2021.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2021.09.007</ArticleId><ArticleId IdType="pubmed">34560276</ArticleId></ArticleIdList></Reference><Reference><Citation>Das DR, Kumar D, Kumar P, Dash BP. Molecular docking and its application in search of antisickling agent from Carica papaya. J Appl Biol Biotech. 2020;8(01):105–116. doi:10.7324/JABB.2020.80117</Citation><ArticleIdList><ArticleId IdType="doi">10.7324/JABB.2020.80117</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai G, Pan Y, Zhang Y, et al. Research advances of molecular docking and molecular dynamic simulation in recognizing interaction between muscle proteins and exogenous additives. Food Chem. 2023;429:136836. doi:10.1016/j.foodchem.2023.136836</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foodchem.2023.136836</ArticleId><ArticleId IdType="pubmed">37453331</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Wei S, Niu S, et al. Network pharmacology prediction and molecular docking-based strategy to explore the potential mechanism of Huanglian Jiedu Decoction against sepsis. Comput Biol Med. 2022;144:105389. doi:10.1016/j.compbiomed.2022.105389</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiomed.2022.105389</ArticleId><ArticleId IdType="pubmed">35303581</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Liu S, Wang B, et al. An updated review on developing small molecule kinase inhibitors using computer-aided drug design approaches. Int J Mol Sci. 2023;24(18):13953. doi:10.3390/ijms241813953</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241813953</ArticleId><ArticleId IdType="pmc">PMC10530957</ArticleId><ArticleId IdType="pubmed">37762253</ArticleId></ArticleIdList></Reference><Reference><Citation>Agu PC, Afiukwa CA, Orji OU, et al. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Sci Rep. 2023;13(1):13398. doi:10.1038/s41598-023-40160-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-40160-2</ArticleId><ArticleId IdType="pmc">PMC10435576</ArticleId><ArticleId IdType="pubmed">37592012</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Wan H, Peng X, Zhou H, Lu Y, He Y. Antiviral effects of Ma Huang Tang against H1N1 influenza virus infection in vitro and in an ICR pneumonia mouse model. Biomed Pharmacother. 2018;102:1161–1175. doi:10.1016/j.biopha.2018.03.161</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.03.161</ArticleId><ArticleId IdType="pubmed">29710534</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya H, Ichinose M, Ikeda K, et al. Inhibition by caffeic acid of the influenza A virus multiplication in vitro. Int J Mol Med. 2014;34(4):1020–1024. doi:10.3892/ijmm.2014.1859</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2014.1859</ArticleId><ArticleId IdType="pubmed">25050906</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan L, Jin H, Liu Y, et al. Main chemical constituents of Changyanning Tablets based on HPLC-Q-TOF-MS/MS. Chin Traditional Herbal Drugs. 2020;51(16):4124–4132.</Citation></Reference><Reference><Citation>Abduljalil JM, Elfiky AA, Elgohary AM. Exploration of natural compounds against the human mpox virus DNA-dependent RNA polymerase in silico. J Infect Public Health. 2023;16(7):996–1003. doi:10.1016/j.jiph.2023.04.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2023.04.019</ArticleId><ArticleId IdType="pmc">PMC10148721</ArticleId><ArticleId IdType="pubmed">37167647</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Qiao J, Chen Y, Tian L, Sun X. Urolithin A inhibits enterovirus 71 replication and promotes autophagy and apoptosis of infected cells in vitro. Arch. Virol. 2022;167(10):1989–1997. doi:10.1007/s00705-022-05471-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-022-05471-1</ArticleId><ArticleId IdType="pubmed">35790643</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Wang P, Chen X, Wang W, Jin Y. Saururus chinensis (Lour). Baill blocks enterovirus 71 infection by hijacking MEK1-ERK signaling pathway. Antiviral Res. 2015;119:47–56. doi:10.1016/j.antiviral.2015.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2015.04.009</ArticleId><ArticleId IdType="pubmed">25912818</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu LL, Yang XB, Huang ZM, Liu HZ, Wu GX. In vivo and in vitro antiviral activity of hyperoside extracted from Abelmoschus manihot (L) medik. Acta Pharmacol Sin. 2007;28(3):404–409. doi:10.1111/j.1745-7254.2007.00510.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1745-7254.2007.00510.x</ArticleId><ArticleId IdType="pubmed">17303004</ArticleId></ArticleIdList></Reference><Reference><Citation>Panchal R, Ghosh S, Mehla R, et al. Antiviral activity of rosmarinic acid against four serotypes of dengue virus. Curr Microbiol. 2022;79(7):203. doi:10.1007/s00284-022-02889-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00284-022-02889-3</ArticleId><ArticleId IdType="pubmed">35612625</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirasago Y, Inamori Y, Suzuki T, et al. Inhibition mechanisms of hepatitis C virus infection by caffeic acid and tannic acid. Biol Pharm Bull. 2019;42(5):770–777. doi:10.1248/bpb.b18-00970</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.b18-00970</ArticleId><ArticleId IdType="pubmed">31061319</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y, Cao Z, Cao L, Ding G, Wang Z, Xiao W. Antiviral activity of chlorogenic acid against influenza A (H1N1/H3N2) virus and its inhibition of neuraminidase. Sci Rep. 2017;10(7):45723. doi:10.1038/srep45723</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep45723</ArticleId><ArticleId IdType="pmc">PMC5385491</ArticleId><ArticleId IdType="pubmed">28393840</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin WY, Yu YJ, Jinn TR. Evaluation of the virucidal effects of rosmarinic acid against enterovirus 71 infection via in vitro and in vivo study. Virol J. 2019;16(1):94. doi:10.1186/s12985-019-1203-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-019-1203-z</ArticleId><ArticleId IdType="pmc">PMC6670152</ArticleId><ArticleId IdType="pubmed">31366366</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi W, Hou X, Li X, et al. Differential gene expressions of the MAPK signaling pathway in enterovirus 71-infected rhabdomyosarcoma cells. Braz J Infect Dis. 2013;17(4):410–417. doi:10.1016/j.bjid.2012.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjid.2012.11.009</ArticleId><ArticleId IdType="pmc">PMC9428059</ArticleId><ArticleId IdType="pubmed">23797008</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera-Torres J, San Jose E. Src tyrosine kinase inhibitors: new perspectives on their immune, antiviral, and senotherapeutic potential. Front Pharmacol. 2019;10:1011. doi:10.3389/fphar.2019.01011</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.01011</ArticleId><ArticleId IdType="pmc">PMC6759511</ArticleId><ArticleId IdType="pubmed">31619990</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan AN, Xu WW, Luo YL, et al. A novel system for predicting liver histopathology in patients with chronic hepatitis B. Medicine. 2017;96(14):e6465. doi:10.1097/MD.0000000000006465</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000006465</ArticleId><ArticleId IdType="pmc">PMC5411194</ArticleId><ArticleId IdType="pubmed">28383410</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen M, Simmonds M. Rosmarinic acid. Phytochemistry. 2003;62(2):121–125. doi:10.1016/s0031-9422(02)00513-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0031-9422(02)00513-7</ArticleId><ArticleId IdType="pubmed">12482446</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh CF, Jheng JR, Lin GH, et al. Rosmarinic acid exhibits broad anti-enterovirus A71 activity by inhibiting the interaction between the five-fold axis of capsid VP1 and cognate sulfated receptors. Emerg Microbes Infect. 2020;9(1):1194–1205. doi:10.1080/22221751.2020.1767512</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1767512</ArticleId><ArticleId IdType="pmc">PMC7448925</ArticleId><ArticleId IdType="pubmed">32397909</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SG, Leu YL, Cheng ML, et al. Anti-enterovirus 71 activities of Melissa officinalis extract and its biologically active constituent rosmarinic acid. Sci Rep. 2017;7(1):12264. doi:10.1038/s41598-017-12388-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-12388-2</ArticleId><ArticleId IdType="pmc">PMC5613005</ArticleId><ArticleId IdType="pubmed">28947773</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Hsieh FC, Lin YJ, et al. Magnesium lithospermate B and rosmarinic acid, two compounds present in Salvia miltiorrhiza, have potent antiviral activity against enterovirus 71 infections. Eur J Pharmacol. 2015;755:127–133. doi:10.1016/j.ejphar.2015.02.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2015.02.046</ArticleId><ArticleId IdType="pubmed">25773498</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng JY, Chen XX, Wang XH, et al. Reducing lipid peroxidation attenuates stress-induced susceptibility to herpes simplex virus type 1. Acta Pharmacol Sin. 2023;44(9):1856–1866. doi:10.1038/s41401-023-01095-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-023-01095-6</ArticleId><ArticleId IdType="pmc">PMC10186316</ArticleId><ArticleId IdType="pubmed">37193755</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukamoto Y, Ikeda S, Uwai K, et al. Rosmarinic acid is a novel inhibitor for Hepatitis B virus replication targeting viral epsilon RNA-polymerase interaction. PLoS One. 2018;13(5):e0197664. doi:10.1371/journal.pone.0197664</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0197664</ArticleId><ArticleId IdType="pmc">PMC5962091</ArticleId><ArticleId IdType="pubmed">29782545</ArticleId></ArticleIdList></Reference><Reference><Citation>Jheng J-R, Hsieh C-F, Chang Y-H, et al. Rosmarinic acid interferes with influenza virus A entry and replication by decreasing GSK3β and phosphorylated AKT expression levels. J Microbiol Immunol Infect. 2022;55(4):598–610. doi:10.1016/j.jmii.2022.04.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2022.04.012</ArticleId><ArticleId IdType="pubmed">35650006</ArticleId></ArticleIdList></Reference><Reference><Citation>Moschovou K, Antoniou M, Chontzopoulou E, et al. Exploring the binding effects of natural products and antihypertensive drugs on SARS-CoV-2: an in silico investigation of main protease and spike protein. Int J Mol Sci. 2023;24(21):15894. doi:10.3390/ijms242115894</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms242115894</ArticleId><ArticleId IdType="pmc">PMC10649947</ArticleId><ArticleId IdType="pubmed">37958877</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>